x

Pesquisar um ensaio clínico

* (*) campo(s) de preenchimento obrigatório

105 Resultado(s)

Ensaio em fase de recrutamento = Ensaio em fase de recrutamento; Ensaio a decorrer = Ensaio a decorrer; Financiado por um membro do IRDiRC =

Ensaio (s) clínico (s) nacional (is)

ALEMANHA

Baden-Württemberg
HEIDELBERG

Ensaio a decorrerENDEAVOR: A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone Versus Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma - DE
Zentrum für Innere Medizin (Krehl-Klinik)
Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie

ALEMANHA

Baden-Württemberg
HEIDELBERG

ESPANHA

Cataluña
BADALONA

ESPANHA

Cataluña
L'HOSPITALET DE LLOBREGAT

FRANCA

AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR

FRANCA

ILE-DE-FRANCE
PARIS

A phase IIa trial testing the efficacy of Bortezomib (Velcade) in patients with advanced Waldenström macroglobulinemia (WM2)
CHU Paris-GH La Pitié Salpêtrière-Charles Foix - Hôpital Pitié-Salpêtrière
Service d'Hématologie clinique

ITALIA

LAZIO
ROMA

Ensaio em fase de recrutamentoEnsaio a decorrerA multicenter, randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma - IT
Sapienza Università di Roma - Dipartimento di Neurologia e Psichiatria
Dipartimento di Biotecnologie Cellulari ed Ematologia

ITALIA

LOMBARDIA
BRESCIA

ITALIA

PIEMONTE
TORINO

ITALIA

TRENTINO ALTO ADIGE
BOLZANO

REINO UNIDO

Devon
PLYMOUTH

A parallel randomised phase II trial of CHOP chemotherapy with or without Bortezomib in relapsed mantle cell lymphoma
Plymouth Derriford Hospital
British National Lymphoma Institute Research Group

REINO UNIDO

Greater London
LONDON

REINO UNIDO

Greater London
LONDON

Ensaio a decorrerA randomized open-label multicenter phase III trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for untreated patients with systemic light-chain (AL) amyloidosis - UK
Joint UCLH/UCL Biomedical Research and Development (R&D) Unit
University College London (UCL) and University College London Hospitals NHS Trust (UCLH)

REINO UNIDO

Hampshire
SOUTHAMPTON

SUICA

Suisse Alémanique
BASEL

Proteasomal Inhibition for Patients With Mis-sense Mutated Dysferlin (Dysferlin)
Universitätsspital Basel
Department of Biomedicine

SUICA

Suisse Alémanique
BERN

Ensaio em fase de recrutamentoEnsaio a decorrerSAKK 36/13: Combination of ibrutinib and bortezomib followed by ibrutinib maintenance to treat patients with relapsed and refractory mantle cell lymphoma; a multicenter Phase I/II trial
University Hospital Inselspital
Universitätsklinik und Poliklinik für Medizinische Onkologie / Brust-und Tumor Zentrum der Frauenklinik

Ensaio (s) clínico (s) multinacional (ais)